MDxHealth SANASDAQ:MDXH
- LAST PRICE2.3000
- TODAY'S CHANGE (%)-0.0700 (-2.9536%)
- Bid / Lots2.2600/ 1
- Ask / Lots2.6300/ 1
- Open / Previous Close2.4000 / 2.3700
- Day Range
- 52 Week Range
- Volume42,720
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDXH |
|---|---|---|
| 09:32 ET | 1499 | 2.43 |
| 09:41 ET | 255 | 2.405 |
| 09:43 ET | 580 | 2.4 |
| 09:50 ET | 250 | 2.38 |
| 09:54 ET | 1000 | 2.36 |
| 10:06 ET | 200 | 2.34 |
| 10:28 ET | 250 | 2.3858 |
| 10:33 ET | 400 | 2.36 |
| 10:44 ET | 5100 | 2.36 |
| 10:51 ET | 200 | 2.33 |
| 11:09 ET | 200 | 2.38 |
| 11:29 ET | 4467 | 2.37 |
| 11:31 ET | 1700 | 2.32 |
| 11:36 ET | 300 | 2.34 |
| 11:40 ET | 1099 | 2.36 |
| 12:41 ET | 817 | 2.31 |
| 12:52 ET | 216 | 2.33 |
| 01:06 ET | 100 | 2.32 |
| 01:12 ET | 800 | 2.3 |
| 01:21 ET | 100 | 2.32 |
| 01:24 ET | 900 | 2.31 |
| 01:28 ET | 500 | 2.3195 |
| 02:11 ET | 1427 | 2.31 |
| 02:29 ET | 1017 | 2.3 |
| 02:33 ET | 300 | 2.32 |
| 02:38 ET | 6789 | 2.28 |
| 02:40 ET | 600 | 2.3 |
| 02:51 ET | 500 | 2.31 |
| 03:00 ET | 983 | 2.3145 |
| 03:02 ET | 800 | 2.32 |
| 03:03 ET | 100 | 2.32 |
| 03:14 ET | 100 | 2.32 |
| 03:21 ET | 100 | 2.32 |
| 03:30 ET | 100 | 2.32 |
| 03:38 ET | 100 | 2.32 |
| 03:39 ET | 1100 | 2.36 |
| 03:50 ET | 5650 | 2.37 |
| 03:52 ET | 100 | 2.3 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MDxHealth SA | 64.7M | 0.0x | --- |
Personalis Inc | 63.5M | -0.5x | --- |
Cidara Therapeutics Inc | 66.2M | -1.9x | --- |
Bioqual Inc | 67.1M | -146.6x | -25.28% |
Protalix Biotherapeutics Inc | 83.3M | 16.6x | --- |
Sorrento Therapeutics Inc | 15.2M | 0.0x | --- |
Company Information
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Contact Information
- Headquarters
- CAP Business Center, Rue d'Abhooz 31HERSTAL, Belgium 4040
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Mark Shaffar
- Chief Executive Officer, Director
- Michael McGarrity
- Chief Financial Officer
- Ron Kalfus
- Executive Vice President, Chief Compliance Officer, General Counsel
- Joseph Sollee
- Executive Vice President & U.S. Chief Operations Officer
- Christopher Thibodeau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $64.7M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 27.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $0.26 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
